Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab Failure for COlorectal Cancer (BEFLICO): An AGEO Multicenter Study.

Cécile Torregrosa 1 Simon Pernot 2 Pauline Vaflard 3 Audrey Perret 4 Christophe Tournigand 5 Violaine Randrian 6 Solene Doat 7 Cindy Neuzillet 3 Valérie Moulin 8 Morgane Stouvenot Gael Roth 9, 10 Tiffany Darbas 11 Benjamin Auberger Tiphaine Godet Marion Jaffrelot Aurélien Lambert 12 Olivier Dubreuil 13 Cassandre Gluszak Alice Bernard-Tessier 3 Anthony Turpin 14, 15 Lola-Jade Palmieri 7, 16 Olivier Bouche 17, 18 Gael Goujon 19 Thierry Lecomte 20, 21, 22 David Sefrioui 23 Christophe Locher 24 Lucien Grados 25 Pauline Gignoux Stéphanie Trager Elise Nassif 26 Angélique Saint 27 Pascal Hammel 28 Cédric Lecaille 29 Mathilde Bureau 30 Marine Perrier 31, 16 Damien Botsen 17, 18, 32 Vincent Bourgeois 33 Julien Taieb 34, 35, 26 Edouard Auclin 35 
Abstract : After failure of first line FOLFOX-bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second-line FOLFIRI increases survival compared to FOLFIRI alone. In this French retrospective multicentre cohort, we included patients with a mCRC treated with either FOLFIRI-aflibercept or FOLFIRI-bevacizumab. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), disease control rate (DCR: CR\,+\,PR\,+\,SD) and safety. We included 681 patients from 36 centers, 326 and 355 in the aflibercept and bevacizumab groups, respectively. Median age was 64.2\,years and 45.2% of patients were men. Most patients had RAS-mutated tumors (80.8%) and synchronous metastases (85.7%). After a median follow up of 31.2~months, median OS was 13.0~months (95% CI: 11.3-14.7) and 10.4~months (95% CI: 8.8-11.4) in the bevacizumab and aflibercept groups, respectively (P\,<\,.0001). Median PFS was 6.0~months (95% CI: 5.4-6.5) and 5.1~months (95% CI: 4.3-5.6) (P\,<\,.0001). After adjustment on age, PS, PFS of first line, primary tumor resection, metastasis location and RAS/BRAF status, bevacizumab was still associated with better OS (HR: 0.71, 95% CI: 0.59-0.86, P~=~.0003). FOLFIRI-bevacizumab combination was associated with longer OS and PFS, and a better tolerability, as compared to FOLFIRI-aflibercept after progression on FOLFOX-bevacizumab.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03735625
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : jeudi 21 juillet 2022 - 14:54:08
Dernière modification le : vendredi 5 août 2022 - 11:57:27

Identifiants

Citation

Cécile Torregrosa, Simon Pernot, Pauline Vaflard, Audrey Perret, Christophe Tournigand, et al.. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab Failure for COlorectal Cancer (BEFLICO): An AGEO Multicenter Study.. International Journal of Cancer, Wiley, 2022, ⟨10.1002/ijc.34166⟩. ⟨hal-03735625⟩

Partager

Métriques

Consultations de la notice

0